Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Viva Biotech Holdings ( (HK:1873) ).
Viva Biotech Holdings has announced the disposal of its equity interest in Arthrosi Therapeutics through a merger. The merger agreement, valued at up to US$1.5 billion, will see Viva receiving an initial payment of approximately US$30 million and potential contingent payments based on regulatory and performance milestones. This transaction is classified as a discloseable transaction under Hong Kong’s Listing Rules, impacting Viva’s financial assets and potentially enhancing its liquidity and strategic focus.
The most recent analyst rating on (HK:1873) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Viva Biotech Holdings stock, see the HK:1873 Stock Forecast page.
More about Viva Biotech Holdings
Viva Biotech Holdings operates in the biotechnology industry, focusing on incubating and investing in early-stage biotech companies. Its primary services include providing financial and strategic support to its portfolio companies, with a market focus on innovative therapeutic solutions.
Average Trading Volume: 6,997,329
Technical Sentiment Signal: Buy
Current Market Cap: HK$4.1B
See more insights into 1873 stock on TipRanks’ Stock Analysis page.